|Title||PharmAbcine, HREC Approval announcement Austin Health|
PharmAbcine, Inc. Korea announced that the Austin Health Human Research Ethics Committee (HREC) notified the company an approval of a phase 2 clinical trial of Olinvacimab (TTAC-0001) in recurrent glioblastoma patients progressed on Bevacizumab including therapy. It is a multicenter, open-label study to evaluate the safety and efficacy of Olinvacimab(TTAC-0001), a fully human monoclonal antibody targeting VEGFR-2 (KDR). Olinvacimab was granted ODD by USFDA for primary and recurrent GBM and the phase II clinical trials that are being prepared in Australia as well as in USA are the key clinical studies tofacilitate the processto bring the drug to market. The phase II clinical trial will be initiated at Austin Health in Australia.